Lastly, the regulatory mechanisms underlying the effects of BBR+Rb1 on cell proliferation, inflammation, adipogenesis, and insulin resistance in the TNF-α-treated adipocytes were studied by introducing RANKL, which is an agonist of the NF-κB pathway. Here, NFKB1 is linked to Insulin resistance.